Coexisting and possible primary extra-gastrointestinal stromal tumors of the pancreas and liver: A single case report

Liu, Lei; Zhu, Yu; Wang, Dongxuan; Yang, Changbin; Zhang, Q I; Li, Xiukun; Bai, Yang

doi:10.3892/ol.2016.4420

Cited by 16 publications

(13 citation statements)

References 32 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other treatment strategies are used in specific clinical situations. In two patients with small tumors, local treatment was attempted with radiofrequency[ 44 ] and microwave[ 45 ] ablation resulting in a satisfying prognosis. TACE is a palliative treatment for patients with unresectable primary hepatic angiosarcoma.…”

Section: Phgist Treatmentmentioning

confidence: 99%

Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors

Qian¹,

Yan²,

Gao³

et al. 2020

WJG

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GIST), which is the most common mesenchymal tumor of the digestive tract, account for 1%-3% of gastrointestinal tumors. Primary stromal tumors outside the gastrointestinal tract are collectively referred to as extra GISTs, and stromal tumors in different regions often have different prognoses. A primary hepatic GIST is a rare tumor with an unknown origin, which may be related to interstitial Cajal-like cells. Although primary hepatic GIST has certain characteristics on imaging, it lacks specific symptoms and signs; thus, the final diagnosis depends on pathological and genetic evidence. This review summarizes all cases of primary hepatic GIST described in the literature and comprehensively analyzes the detailed clinical data of all patients. In terms of treatment, local resection alone or with adjuvant therapy was the prioritized choice to obtain better disease-free survival and longer survival time. For advanced unresectable cases, imatinib mesylate was applied as the first-line chemotherapy agent. Moreover, transcatheter arterial chemoembolization, radiofrequency ablation, and microwave ablation were shown to improve overall survival for selected patients. Liver transplantation was a final treatment option after resistance to chemotherapy developed.

show abstract

Section: Phgist Treatmentmentioning

confidence: 99%

Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors

Qian¹,

Yan²,

Gao³

et al. 2020

WJG

View full text Add to dashboard Cite

show abstract

“…The patients comprised 14 males [9,11,13,17,19,22,23,26,27,29,31–33,36] and 13 females [10,14,16,18,20,21,24,25,28,30,34,35] with the median age of 61 years (range: 17–79). There were no specific symptoms for the patients with primary hepatic EGIST.…”

Section: Literature Reviewmentioning

confidence: 99%

“…Regarding their treatment, 21 patients [10,11,13–17,19–21,23,25,27,30–36,38] underwent curative hepatectomy, 1 patient [22] underwent laparotomy radiofrequency ablation (RFA) due to a tumor size of 5.1 cm, 1 patient [24] adopted microwave ablation (MWA) for a tumor size of 2.4 cm and 1 patient [29] with multiple huge cystic masses (the smallest 1 was more than 20 cm) underwent repeated drainage, other 4 patients [9,18,26,28] were not treated surgically. For adjuvant therapy, imatinib which is also known as Gleevec, was prescribed for 10 patients [9,11,14,21,24,25,32,34–36] including 1 patient [9] who did not undergo surgery. Morphologically, 23 studies [9–11,13–17,19,21–26,29–36] reported the cell type, of which 19 (82.6%) cases [9–11,13,15–17,19,21–24,26,29,30,33–36] had spindle cells, 2 cases [31] (including current case) had epithelioid cells, and 3 cases [14,25,32] had a mixture of cell types.…”

Section: Literature Reviewmentioning

confidence: 99%

“…For adjuvant therapy, imatinib which is also known as Gleevec, was prescribed for 10 patients [9,11,14,21,24,25,32,34–36] including 1 patient [9] who did not undergo surgery. Morphologically, 23 studies [9–11,13–17,19,21–26,29–36] reported the cell type, of which 19 (82.6%) cases [9–11,13,15–17,19,21–24,26,29,30,33–36] had spindle cells, 2 cases [31] (including current case) had epithelioid cells, and 3 cases [14,25,32] had a mixture of cell types. The mitotic count in the tumor was reported in 19 studies [9–11,13,14,16,21,22,24,25,27,29–34,36] with a range of 0 to 75 mitoses/50 high-power fields (HPF).…”

Section: Literature Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Primary hepatic gastrointestinal stromal tumor with right adrenal gland invasion

Zhang

2019

Medicine

View full text Add to dashboard Cite

Introduction: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors that mainly occur in the gastrointestinal tract. The GISTs that are sporadically reported in extra-gastrointestinal regions are named as extra-gastrointestinal stromal tumors (EGISTs). However, the primary EGISTs that originate from the liver are rare. Patient Concerns: A 64-year-old female presenting with right upper abdominal pain and thirsty for more than 20 days. Diagnosis: A diagnosis of a 15 × 14 × 7 cm liver mass located in the posterior right lobe of liver and spread to the right adrenal gland was confirmed. Pathological results showed that the tumor was mainly composed of epithelial cells and tested positive for CD117 and SDHB (succinate dehydrogenase complex iron sulfur subunit B). The gene mutational analyses for c-Kit and platelet-derived growth factor receptor alpha exons revealed negative results. Fluorescence in situ hybridization of murine double minute 2 produced negative fluorescence results which distinguished it from dedifferentiated liposarcomas. The postoperative gastroduodenal and colorectal endoscopy did not find any neoplastic lesions. To this end, the diagnosis of primary hepatic EGIST of wild type nature was confirmed. Interventions: The patient received right hepatectomy and adrenalectomy, no postoperative chemotherapy was administered. Outcomes: The patient died 11 months after surgery due to tumor metastasis. Conclusion: Primary hepatic EGIST is a rare and complicated disease of liver, a multidisciplinary team is necessary in diagnosis and treatment of primary hepatic EGIST.

show abstract

“…The clinical features of GISTs change due to the size and site of the tumor, and GISTs located in the gastrointestinal tract are more aggressive than those arising in the stomach [3]. For the treatment of GISTs, surgery and drugs achieve satisfactory therapeutic effects at the present stage [7], and the main treatments for GISTs are resection and anticancer and biological therapies, such as imatinib mesylate [8]. However, both extensive resections and limited local resections only have a small amount of experimental data, and traditional complete surgical resection with adjuvant therapy imminently improves survival in GISTs with a high risk of recurrence or metastasis [9,10].…”

Section: Introductionmentioning

confidence: 99%

ShRNA‐mediated BMI‐1 gene silencing inhibits gastrointestinal stromal tumor cell telomerase activity and enhances apoptosis

Wang

Xiao

et al. 2018

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GISTs) are the most frequently occurring mesenchymal tumors of the gastrointestinal tract. Telomerase activity is well acknowledged as a critical factor in oncogenesis. The objective of the present study is to evaluate the effect of BMI gene silencing on proliferation, apoptosis and telomerase activity in human GIST882 cells. GIST882 cells were transfected with a eukaryotic expression vector of an shRNA fragment. The silencing efficiency in the GIST882 cells was determined by RT‐qPCR and a western blot analysis. After the shRNA‐BMI‐1 plasmid was transfected into the GIST882 cells and nude mice, a cell counting kit‐8 (CCK‐8) assay and flow cytometry were utilized to detect the GIST882 cell proliferation, the apoptosis rate and the cell cycle. Tumor growth was observed by tumor xenograft in nude mice. Telomerase activity and telomere length were detected by a Southern blot and a target region amplified polymorphism. The shRNA‐BMI‐1 recombinant plasmid was successfully constructed. The mRNA and protein expression of the BMI‐1 gene in GIST882 cells was suppressed by the shRNA‐BMI‐1 recombinant plasmid. Meanwhile, BMI‐1 gene silencing inhibited the cell proliferation, tumor growth, and cell cycle in the GIST882 cells. However, cell apoptosis was increased and telomerase activity was decreased with the silencing of the BMI‐1 gene. Collectively, the results of this study suggest that silencing the BMI‐1 gene may provide a new target for the treatment of GISTs.

show abstract

Coexisting and possible primary extra-gastrointestinal stromal tumors of the pancreas and liver: A single case report

Cited by 16 publications

References 32 publications

Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors

Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors

Primary hepatic gastrointestinal stromal tumor with right adrenal gland invasion

ShRNA‐mediated BMI‐1 gene silencing inhibits gastrointestinal stromal tumor cell telomerase activity and enhances apoptosis

Contact Info

Product

Resources

About